Lupin has signed an exclusive licensing, supply, and distribution agreement with China-based Gan Lee Pharmaceuticals for Bofanglutide, a novel injection for treating type 2 diabetes and aiding weight management in adults. This pact grants Lupin exclusive rights for India, aiming to strengthen its diabetes portfolio and expand its presence in the obesity market. Both companies expressed commitment to addressing chronic metabolic diseases and showcasing global biopharmaceutical innovation.